Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4006355 | 0.76 | CHEK1 (1.00) | CHEK1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6508962 | 0.73 | CHEK1 (0.74) | CHEK1 | |
| SCHEMBL6507585 | 0.73 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL6046750 | 0.73 | CHEK1 (0.74) | CHEK1AURKAKDRAURKBJAK1 | |
| SCHEMBL6514882 | 0.73 | CHEK1 (0.74) | CHEK1KIF11 | |
| Hydrochloric Acid SCHEMBL6508722 | 0.72 | CHEK1 (0.72) | CHEK1KIF11 | |
| SCHEMBL6509801 | 0.69 | CHEK1 (0.67) | CHEK1 | |
| SCHEMBL4018879 | 0.68 | CHEK1 (0.51) | CHEK1KIF11 | |
| SCHEMBL13811829 | 0.68 | CHEK1 (0.51) | CHEK1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5129229 | 0.67 | CHEK1 (0.50) | CHEK1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550477-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550477-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550477-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090023767-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-01-22 | — | — | US | disclosed |
| US-20090023767-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-01-22 | — | — | US | disclosed |
| US-20090023767-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-01-22 | — | — | US | disclosed |
| EP-1976523-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| EP-1835918-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007081572-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007081572-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2006074281-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | CHEK1 1/4885GRIN2D 4618/4885GRIN3B 3909/4885 |
| US-20090023767-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | CHEK1 1/4885GRIN2D 4727/4885GRIN3B 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.